Human sensitivity to PhIP: A novel marker for prostate cancer risk
Human sensitivity to PhIP: A novel marker for prostate cancer risk
复制标题
DOI：
10.1016/j.mrfmmm.2006.05.023
复制
发表时间：
2006-10-10
影响因子：
2.3
通讯作者：
Strom, Sara S.
中科院分区：
文献类型：
--
作者：
El-Zein, Randa;Etzel, Carol J.;Strom, Sara S.
2-氨基-1-甲基-6-苯基咪唑[4，5-B]吡啶（PhIP）与大鼠结肠、前列腺和乳腺肿瘤的发生有关。在这项研究中，我们开发了一种改良的体外诱变剂敏感性试验，与活化的PhIP（N-OH-PhIP）作为挑战诱变剂和染色体畸变为终点，并将其应用于试点前列腺癌病例对照研究的81例和84个年龄和种族匹配的对照。我们的结果显示，病例中基线断裂显著更高，平均值+/-S. E。= 1.86 +/- 0.23，对照组为0.96 +/- 0.14; P = 0.006。高基线断裂的个体（在对照中位数处二分）PC风险增加36%（OR = 1.36; 95%CI = 1.08-1.72）。在分层分析中，高基线断裂与年轻参与者相关（
2-Amino-1-methyl-6-phenylimidazo[4,5-b]pyridine (PhIP) has been implicated in the development of colon, prostate and mammary gland tumors in rats. In this study, we developed a modified in vitro mutagen sensitivity assay, with activated PhIP (N-OH-PhIP) as the challenge mutagen and chromosome aberrations as the endpoint, and applied it in a pilot prostate cancer case-control study of 81 cases and 84 age and ethnicity-matched controls. Our results showed significantly higher baseline breaks among the cases, mean +/- S.E. = 1.86 +/- 0.23 versus 0.96 +/- 0.14 in controls; P = 0.006. Individuals with high baseline breaks (dichotomized at the control median) had a 36% increased risk for PC (OR = 1.36; 95% CI = 1.08-1.72). In stratified analysis, high baseline breaks was associated in younger participants (